REGNCongressional Stock Trades
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
Congressional stock trades in Regeneron Pharmaceuticals Inc (REGN) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
14
Politicians Trading
9
Last Traded
Jul 7, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Ro KhannaD | Aug 7, 2026 | Jul 7, 2026 | Buy | $1,001 - $15,000 | +16.06% |
| Gilbert Ray Cisneros, Jr.D | Dec 15, 2025 | Nov 18, 2025 | Buy | $1,001 - $15,000 | +8.20% |
| Julie JohnsonD | Feb 12, 2025 | Jan 15, 2025 | Buy | $1,001 - $15,000 | +11.57% |
Price History
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).